Antibody-Drug Conjugates for Breast Cancer — Year in Review Series on Relevant New Datasets and Advances
Oncology Today with Dr Neil Love
00:00
ADCs in Triple-Negative First-Line Therapy
Sara reviews moving ADCs into first-line TNBC, including SG+pembrolizumab, SG alone, and DatoDXD data.
Play episode from 32:41
Transcript
